Kamla Nehru College of Pharmacy Butibori, Nagpur Maharashtra (India)- 441108
Diabetes mellitus is a group of common endocrine diseases characterized by sustained high blood sugar levels and physiological dysfunctions characterized by hyper-glycemia resulting directly from insulin resistance, inadequate insulin secretion, or excessive glucagon secretion. Commonly reported manifestations are Polydipsia, Polyuria, Polyphagia, Weight loss, etc. Diabetes mellitus classification is Type 1 diabetes (T1D) is an autoimmune disorder leading to the destruction of pancreatic beta-cells. Type 2 diabetes (T2D), which is much more common, is primarily a problem of progressively impaired glucose regulation due to a combination of dysfunctional pancreatic beta cells and insulin resistance. The purpose of this article is to review the basic science of type 2 diabetes and its complications, and to discuss the most recent treatment.
A metabolic disease called diabetes mellitus is typified by elevated blood glucose levels brought on by a malfunctioning or relative lack of insulin secretion. Chronic hyperglycaemia is linked to an increased risk of cardiovascular disease (CVD) and relatively specific long-term microvascular consequences that affect the kidneys, nerves, and eyes. The bloodstream is responsible for delivering glucose to the body's cells, which need it as a food source. However, without the hormone insulin, they are unable to absorb and use glucose. However, without the hormone insulin, they are unable to absorb and use glucose. The pancreas produces this hormone, insulin. Insulin functions similarly to a key that opens the door to separate our blood sugars from cells. The hallmark of diabetes mellitus is a disruption in the metabolism of fat, protein, and carbohydrates brought on by a total or partial lack of insulin action and/or secretion.[1] In the context of insulin resistance, diabetes is a complicated, long-term condition marked by inadequate β-cell insulin production. One of the biggest challenges to global health today is diabetes, which ranks among the top three noncommunicable diseases and is responsible for more than 80% of all early deaths from noncommunicable diseases. It is also one of the top 10 causes of mortality globally. Its widespread occurrence worldwide. Its global prevalence has rapidly increased over the past several decades.[2]
Fig no. 1. Elevation of blood glucose
Risk factors for Diabetes mellitus:
Symptoms of Diabetes mellitus:
A healthy physiological state is created and maintained by the coordinated action of several systems and pathways in the human body. The ability of the body to maintain homeostasis, or a steady, stable condition, is at the heart of these processes. In different organs, an injury or diseased state develops as a result of an imbalance in homeostasis. Diabetes mellitus. impairs a person's capacity to control blood glucose levels, which can lead to a number of serious and moderate problems. [4,13]
The chronic illness known as type I diabetes mellitus (T1DM) is typified by the body's incapacity to manufacture insulin as a result of the autoimmune destruction of the pancreatic beta cells. It causes hyperglycaemia. This kind was once known as "juvenile diabetes" or "insulin-dependent diabetes mellitus" (IDDM).[3] According to the International Diabetes Federation, 8.8% of the adult population globally has diabetes14. kind 2 diabetes mellitus (T2DM) is the most prevalent kind of diabetes, with only 10–15% of those with diabetes having T1DM. Nonetheless, T1DM is the most prevalent type of diabetes in children, affecting 500,000 children worldwide at the moment.[5]
Risk factor for type I Diabetes mellitus:
Symptoms of type I Diabetes mellitus:
insulin resistance as a backdrop for the increasing insulin secretary malfunction. Insulin resistance is a common feature of this kind of diabetes. This kind was once known as "adult-onset diabetes" or "non-insulin-dependent diabetes mellitus" (NIDDM). Being overweight and not exercising enough are the main causes. The body produces insulin when insulin resistance occurs, however insulin sensitivity is decreased and the insulin does not function as well as it should.[5] Two issues result from the glucose's improper entry into the body's cells: • An accumulation of glucose in the blood; and • The cells' inability to get the glucose required for growth and energy. Type 2 diabetes is a worldwide health crisis. In the U.S., 20.8 million are affected at a cost of 2 billion in 2002, and the numbers will likely continue to increase. The Centres for Disease Control and Prevention estimates there are more than 40 million people in the U.S. with prediabetes. Given that the Diabetes Prevention Program showed an 11% yearly conversion rate of impaired glucose tolerance (IGT) to diabetes, there could be as many as 4 million new cases each year. Furthermore, the incidence of type 2 diabetes is rising around the world, with a recent prediction that the worldwide prevalence will increase from 2.8% in 2000 to 4.4% in 2030, resulting in 366 million affected people. [6]
Risk factor for type ? Diabetes mellitus:
Symptoms of type ? Diabetes mellitus:
Gestational diabetes mellitus (GDM) is the term used to describe glucose intolerance that is discovered or first experienced during pregnancy. Pregnant women with undetected asymptomatic Type 2 diabetes mellitus and those who develop Type 1 diabetes mellitus are both considered to have gestational diabetes mellitus (GDM). In gestational diabetes mellitus (GDM), a hormone produced by the placenta interferes with the body's ability to use insulin. Rather than being absorbed by the cells, glucose accumulates in the circulation.[7]
Risk factor for gestational Diabetes mellitus:
Symptoms of gestational Diabetes mellitus:
Over the previous three decades, the number of people with diabetes mellitus has more than doubled globally.2. Type 2 diabetes mellitus (T2DM) accounted for 90% of the estimated 285 million individuals with diabetes mellitus globally in 2010.One By 2030, it is anticipated that 439 million people worldwide would have diabetes mellitus, accounting for 7.7% of all adults aged 20 to 79 nationwide.[8]
Fig no. 2: In each box, the top and middle values represent the number of people with diabetes mellitus (in millions) in each of seven world regions (depicted with different colours) for 2010 and 2030, respectively; the bottom value is the percentage increase from 2010 to 2030. The number of people globally with diabetes mellitus is projected to rise from 285 million in 2010 to 439 million by 2030, a 54% increase.
Fig no. 3: The number of people with diabetes mellitus and IGT (in millions) by region among adults aged 20–79 years for the years 2010 and 2030. Data courtesy of the International Diabetes Federation Diabetes Atlas.114 Abbreviation: IGT, impaired glucose tolerance.
The proportion of glycosylation of the haemoglobin A1C chain is known as A1C, and it roughly represents the average blood glucose levels throughout the preceding two to three months due to the body's gradual red blood cell turnover.[9]
Table no.1: Glucose level in A1C test.
|
Diagnosis |
A1C |
|
Normal |
Below 5.7% |
|
Prediabetes |
5.7 to 6.4% |
|
Diabetes |
6.5% or above |
For at least eight hours prior to the test, you should only consume water (fast) and nothing else. Blood sugar can be significantly impacted by food. Your provider can view your baseline blood sugar levels with this test.[10]
Table no.2: Glucose level in Fasting blood glucose test.
|
Diagnosis |
Range |
|
Normal |
Less than 99 mg/dL (decilitre) |
|
Prediabetes |
100 to 125 mg/dL |
|
Diabetes |
126mg/dL or higher |
The ability of the body to absorb, utilize, and eliminate glucose from the bloodstream is measured by the oral glucose tolerance test (OGTT). It is safe for both adults and children and is also known as a glucose tolerance test. You don't eat for a time before doing the test, and then you sip a syrupy solution. To find out how your body is responding to the sugar in the beverage, a few blood samples are drawn.[11]
Table no.3: Glucose level in Oral glucose tolerance test.
|
Diagnosis |
Oral glucose tolerance test |
|
Normal |
139mg/dL or below (decilitre) |
|
Prediabetes |
140 to 199 mg/dL |
|
Diabetes |
|
When you exhibit signs of diabetes and your doctor does not want to wait until you have fasted for eight hours, they may perform the random plasma glucose test to make the diagnosis. This blood test can be performed at any time.[12] When blood glucose levels are 200 mg/dL or higher, diabetes is diagnosed.
Currently, there are many different ways to manage diabetes mellitus. It may be difficult for the doctors to find the proper combination. Doctors choose the appropriate course of treatment based on the type and severity of diabetes mellitus.
Different treatment options for Diabetes Mellitus;
There's no specific diabetes diet. However, it's important to centre your diet around:
Maintaining a healthy weight or reducing weight requires exercise. It also helps with managing blood sugar. Before beginning or altering your exercise regimen, consult your healthcare professional to be sure the activities are safe for you.
Losing weight improves blood pressure, cholesterol, triglycerides, and blood sugar regulation. After lowering even 5% of your body weight, overweight people may start to notice changes in these areas. However, the health benefits increase with the amount of weight you reduce. It may be advised in certain situations to reduce body weight by up to 15%.
To ensure that you stay within your goal range, your healthcare practitioner will advise you on how frequently to check your blood sugar level. For instance, you might need to check it once daily and either before or after working out. You might need to check your blood sugar several times a day if you use insulin.
A number of non-insulins based oral therapies have emerged for the treatment of type 2 DM. These are categorized under the following sub-headings [14].
Several plant extracts were tested to corroborate their synergistic and multifactorial acts towards DM. Here are represented a few of those [15].
Table no.4: Herbal drug for treatment of Type ? D.M.:
|
Drug |
Activity |
|
The increased expression of PPAR-y and reduced leptin expression in white adipose tissues, as well as the promotion of GLUT4 expression in skeletal muscles. Regardless the mechanisms, its extracts improved insulin sensitivity, glucose tolerance and insulin signalling pathway [16]. |
|
saponin and polysaccharide constituents which might be involved in the double activation of AMP-activated protein kinase (AMPK) and PPAR- y [17]. They act with different mechanisms including the stimulation of insulin biosynthesis and its secretion. Furthermore, consumption of ginseng increases insulin-regulated receptor (GLUT-4) in skeletal muscle and in liver and increases lipoprotein lipase (LPL) and PPAR-in adipose tissues [18]. |
|
Inhibit carbohydrate metabolic enzymes leading to hypoglycaemic effects. Furthermore, its seeds can decrease glucose-6-phosphatase and fructose-1,6-bisphosphatase in liver and kidney [19]. |
|
Improvement in insulin resistance and the suppression of gluconeogenesis. |
|
Lower blood glucose and promoting the secretion of insulin. |
By attaching to the sulfonylurea receptor (SUR) of the ATP-sensitive potassium channel on pancreatic β cells, these medications—particularly sulfonyl urea’s and metiglinides—increase the amount of insulin secreted by the pancreas. [20]
Table no.5: Insulin Secretagogues drug for treatment of Type ? D.M.:
|
Drugs |
Side effect |
Tolbutamide Chlorpropamide Tolazamide Aceto-hexamide [21]
Glibenclamide Glipizide Glimepiride [21] |
Low blood sugar level Dizziness Sweating Confusion Nervousness [22] Hunger Weight gain Skin reaction Stomach upset Dark coloured urine. |
It functions by enhancing the body's reaction to natural insulin, lowering intestinal glucose absorption, and lowering the quantity of glucose the liver produces. By promoting glycolysis and inhibiting gluconeogenesis, biguanides lower the amount of glucose produced by the liver. By raising insulin receptor activation, they raise insulin signalling.[23]
Table no.6: Biguanides drug for treatment of Type ? D.M.:
|
Drugs |
Side effect |
|
Metformin Phenformin Buformin |
|
Another name for the insulin sensitizers is PPARs, or peroxisome proliferator activated receptor agonists. PPARs control the metabolism of proteins and carbohydrates and preserve glucose homeostasis. These are ligand-activated transcription factors that belong to the nuclear hormone receptor superfamily [25].
Table no.7: Insulin Sensitizers drug for treatment of Type ? D.M.:
|
Drug |
Primary tissue target |
Mechanism of action |
Side effect |
|
liver |
Inhibition of hepatic glucose output/insulin sensitivity. |
|
Pioglitazone Rosiglitazone Ciglitazone |
Adipose, muscle & liver |
Insulin-sensitising/anti- inflammatory. |
|
Muraglitizar Tesaglitazar Aleglitazar Ragaglitizar Naveglitazar Saroglitazar[27] |
Adipose, muscle & liver [26] |
Insulin-sensitising, anti- inflammatory & lipid lowering. |
|
Sitagliptin Saxagliptin linagliptin |
Pancreatic ? cells. |
Stimulation of insulin release and B-cell differentiation [26]. |
|
By shifting the undigested carbohydrate toward the distal portion of the small intestine and colon, AGIs slow down the process of carbohydrate absorption in the gastrointestinal tract and assist lower postprandial hyperglycaemia [29].
Table no.8: Alpha Glucosidase Inhibitors drug for treatment of Type ? D.M.:
|
Drugs |
Side effect |
|
Valises Miglitol [30] |
|
A single chain of 37 amino acids makes up the hormone amylin. It is co-secreted by the pancreatic β cells together with insulin. It keeps blood glucose levels stable during fasting and after meals by delaying stomach emptying and inhibiting glucagon secretion. By altering the brain's appetite centre, it controls how much food is consumed [32].
Table no.9: Amylin antagonists’ drug for treatment of T ? D.M.:
|
Drugs |
Side effect |
|
Pramlintide acetate |
|
Reabsorption of glucose in proximal convoluted tubule (PCT) is done by transporter, sodium glucose co-transporter (SGLT) [34]. SGLT2 inhibitors suppress the SGLT2 found in PCT which limits reabsorption of glucose and improves the elimination of glucose in urine. As glucose is eliminated in urine, the glucose level in the blood is maintained and other glycaemic parameters are maintained [35].
Table no.10: Sodium glucose co-transporter 2 inhibitors drug for treatment of Type ? D.M.:
|
Drug |
Side effect |
|
Canagliflozin Dapagliflozin Empagliflozin Ipragliflozin Luseogliflozin Tofogliflozin [36]. |
|
Some drawbacks of traditional drug delivery methods include reduced potency or altered effects as a result of drug metabolism, lack of target specificity, and ineffectiveness due to incorrect or ineffective dosage [37, 38]. Because of its advantages in lowering the frequency of doses, improving bioavailability, preventing degradation in an acidic stomach environment, and providing tailored therapeutic efficacy with fewer side effects, novel drug delivery systems (NDDSs) have become one of the newest and most promising topics in recent years [39].
Table no.11: Novel drug delivery system drug for treatment of Type ? D.M.:
|
Type of delivery system |
Class of drug |
Name of drug |
|
Liposome |
Biguanides |
Metformin |
|
Incretin Mimetics
|
Glucagon-like peptide-1 (GLP- 1) Liraglutide [40] |
|
|
Sulfonylureas |
Gliclazide |
|
|
Insulin Secretagogues |
Repaglinide [41] |
|
|
Niosome |
Biguanides |
Metformin [42] |
|
Insulin Sensitizers – Thiazolidinediones |
Pioglitazone
|
|
|
Insulin Secretagogues |
Repaglinide [43] |
|
|
Polymeric Nanoparticles |
Biguanides |
Metformin |
|
|
Sulfonylureas
|
Glipizide Glimepiride Glibenclamide |
|
Insulin Sensitizers – Thiozolidinediones |
Pioglitazone [44] |
|
|
Insulin Secretagogues |
Repaglinide |
|
|
Nano-emulsion |
Insulin Secretagogues |
Repaglinide |
|
Insulin Sensitizers – Thiazolidinediones |
Pioglitazone
|
|
|
Self-nano-emulsifying drug delivery systems |
Sulfonylureas
|
Glipizide Glimepiride Glibenclamide |
|
Insulin Secretagogues |
Repaglinide |
|
|
Carbon Nanotubes |
Biguanides |
Metformin |
|
Nanocrystal |
Sulfonylureas |
Gliclazide |
|
Nano-formulations in Transdermal patches (TDPs) |
Biguanides |
Metformin |
|
Sulfonylureas |
Glimepiride |
|
|
Insulin Secretagogues |
Repaglinide [45] |
CONCLUSION:
Type ? DM is a metabolic disease that can be prevented through lifestyle modification, diet control, control of overweight, obesity and the medication. Education of the population is still key to the control of this emerging epidemic. Novel drugs are being developed, yet no cure is available in sight for the disease, despite new insight into the pathophysiology of the disease. Management should be tailored to improve the quality of life of individuals with type ? DM.
REFERENCES
Pravin Bhoyar*, Nitin Padole, Nilakshi Dhoble, Pankaj Dhapke, Jagdish Baheti, Type ? Diabetes Mellitus and Their Managements, Int. J. of Pharm. Sci., 2025, Vol 3, Issue 2, 1869-1880. https://doi.org/ 10.5281/zenodo.14913424
10.5281/zenodo.14913424